文献速递消化系统肿瘤支持与姑息治疗

治疗前维生素D缺乏与胰腺癌炎症标志物升高及总生存期缩短相关

Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.
PubMed 文献 · Eur J Cancer · 2020-12-17

基于BIOPAC前瞻性队列1267例胰腺导管腺癌患者,治疗前血清维生素D缺乏者IL-6、YKL-40和CRP中位水平最高。可切除I-II期患者中,维生素D缺乏者中位OS为18.3个月,短于充足者的29.7个月,死亡HR为1.55;晚期患者中维生素D水平与OS无显著相关。

要点

  • 治疗前维生素D缺乏与胰腺癌各分期炎症标志物升高相关
  • 可切除I-II期胰腺癌中维生素D缺乏者OS更短
  • 晚期胰腺癌中维生素D水平与OS无显著相关

核心结论

  • 维生素D缺乏与所有分期胰腺导管腺癌患者炎症标志物升高相关。
  • 可切除I-II期患者中维生素D充足者OS高于缺乏者,但晚期患者中维生素D水平与生存无相关性。

研究设计与样本

  • 前瞻性BIOPAC研究(NCT03311776)纳入2008年7月至2018年9月1267例胰腺导管腺癌患者。
  • 治疗前测定血清维生素D、IL-6、YKL-40和CRP水平,按维生素D水平分组:充足>50 nmol/L、不足25-50 nmol/L、缺乏<25 nmol/L。

主要发现

  • 所有肿瘤分期中,维生素D缺乏患者IL-6中位水平最高,为8.3 pg/mL(范围0.7-91)。
  • 维生素D缺乏患者YKL-40中位水平最高,为177 ng/ml(范围25-5279)。
  • 维生素D缺乏患者CRP中位水平最高,为15.5 mg/L(范围0.8-384)。
  • 可切除I-II期维生素D缺乏患者中位OS为18.3个月(95%CI 12.1-31.5个月),充足者为29.7个月(95%CI 22.3-36.1个月)。
  • 可切除I-II期维生素D缺乏者死亡HR为1.55(95%CI 1.04-2.31;p=0.03)。

关键数值与推荐

  • 维生素D分组阈值:充足>50 nmol/L,不足25-50 nmol/L,缺乏<25 nmol/L。
  • 可切除I-II期维生素D缺乏者中位OS 18.3个月(95%CI 12.1-31.5个月),充足者29.7个月(95%CI 22.3-36.1个月)。
  • 可切除I-II期维生素D缺乏者死亡HR 1.55(95%CI 1.04-2.31;p=0.03)。

临床怎么用

  • 胰腺癌患者治疗前可检测血清维生素D水平,缺乏者提示炎症负荷较高。
  • 可切除I-II期胰腺癌患者维生素D缺乏与更短OS相关,可能需关注围手术期营养与维生素D状态。
  • 晚期胰腺癌中维生素D水平与生存无显著相关,不应据此判断预后。

局限性

  • 维生素D补充对胰腺癌生存的影响尚不明确,需未来研究进一步探讨。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitamin D deficiency and inflammation are associated with increased mortality. We investigated the relationship between pre-treatment serum vitamin D levels, inflammatory biomarkers (IL-6, YKL-40 and CRP) and overall survival (OS) in pancreatic ductal adenocarcinoma (PDAC) patients. METHODS: Pre-treatment serum vitamin D, IL-6, YKL-40 and CRP levels were determined in 1,267 patients with PDAC enrolled from July 2008 to September 2018 in the prospective BIOPAC study (NCT03311776). The patients were grouped according to vitamin D levels: sufficient >50 nmol/L, insufficient 25-50 nmol/L and deficient <25 nmol/L. RESULTS: Across all tumour stages, vitamin D-deficient patients had the highest median levels of IL-6 (8.3 pg/mL, range 0.7-91), YKL-40 (177 ng/ml, range 25-5279) and CRP (15.5 mg/L, range 0.8-384). The resected stage I and II patients with vitamin D deficiencies had a shorter median OS, 18.3 months (95% CI, 12.1-31.5 months) than those with sufficient levels, 29.7 months (95% CI, 22.3-36.1 months), and the hazard ratio for death was 1.55 (95% CI, 1.04-2.31; p = 0.03). In advanced PDAC, there was no significant difference in OS between the vitamin D groups. CONCLUSIONS: Vitamin D deficiency was associated with increased inflammatory biomarkers in all PDAC stages. The resected stage I and II patients with sufficient vitamin D levels had a higher OS than those with a vitamin D deficiency. However, there was no correlation between vitamin D levels and survival in advanced PDAC. Future studies need to investigate vitamin D supplementation effects on survival in PDAC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rasmussen LS, Yilmaz MK, Falkmer UG, et al. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Eur J Cancer. 2020. PMID: 33341448. doi:10.1016/j.ejca.2020.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。